On Tuesday, Following Stocks were among the “Top Losers” of U.S. Stock Market: Cliffs Natural Resources Inc. (NYSE:CLF), Iconix Brand Group, Inc. (NASDAQ:ICON), DryShips, Inc. (NASDAQ:DRYS), ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
Cliffs Natural Resources Inc. (NYSE:CLF), with shares declined -4.94%, closed at $4.81.
Iconix Brand Group, Inc. (NASDAQ:ICON), with shares dropped -7.47%, settled at $33.67.
DryShips, Inc. (NASDAQ:DRYS), with shares dipped -6.17%, and closed at $0.76.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), plummeted -7.24%, and closed at $10.77.
Latest NEWS regarding these Stocks are depicted underneath:
Cliffs Natural Resources Inc. (NYSE:CLF)
Cliffs Natural Resources Inc. (CLF), declared that its Board of Directors declared a quarterly cash dividend on the Corporation’s 7.00% Series A Mandatory Convertible Preferred Stock, Class A, of $17.50 per share, which is equivalent to about $0.4375 per depositary share, each representing 1/40th of a share of Series A preferred stock. The cash dividend will be payable on May 1, 2015 to shareholders of record as of the close of business on April 15, 2015.
Cliffs Natural Resources Inc., a mining and natural resources corporation, produces iron ore and metallurgical coal. It operates five iron ore mines that produces iron ore pellets in Michigan and Minnesota; Koolyanobbing complex situated in northeast of the town of Southern Cross, which produces lump and fines iron ore; and two metallurgical coal mines located in Alabama and West Virginia.
Iconix Brand Group, Inc. (NASDAQ:ICON)
Formerly on March 16, Iconix Brand Group, Inc. (ICON), declared that it has attained the remaining 50% of Iconix China from its joint venture partner Novel Fashion Brands Limited, owned by the Chou family, for $56.4 million, of which $40.4 million was paid in cash and $16 million was paid in the Corporation’s ordinary stock.
“We view China as a major growth opportunity. Through Silas and Veronica Chou’s expertise and relationships, Iconix China has successfully launched nine of our brands with more than 900 standalone stores, shop-in-shops and counters throughout China,” stated Neil Cole, Chairman and CEO of Iconix. “Now that our business has gained sufficient scale, we have decided to attain administration and control of the business, consistent with the next phase of our international growth strategy.”
Iconix Brand Group, Inc., a brand administration corporation, owns, licenses, and markets a portfolio of consumer brands across women’s, men’s, entertainment, and home primarily in the United States and internationally.
DryShips, Inc. (NASDAQ:DRYS)
DryShips, Inc. (DRYS), declared that it has reached firm sales contracts with entities controlled by the Corporation’s Chairman and Chief Executive Officer, George Economou, to sell its four Suezmax tankers, Vilamoura, Lipari, Petalidi and Bordeira, for an en-bloc sales price of $245 million. In addition, it has reached contracts with entities controlled by Mr. Economou to potentially sell its six Aframax tankers, Belmar, Calida, Alicante, Mareta, Saga and Daytona. The contracts to sell the Aframax fleet are not effective until the purchaser confirms his unconditional acceptance latest by June 30, 2015.
Under the terms of the firm sales contracts on the four Suezmax tankers, the purchasers will pay upfront 20% to DryShips and the balance purchase price will be due on delivery which will be between July 1, 2015 and October 31, 2015, at the Corporation’s option.
Under the terms of the contracts on the six Aframax tankers, the purchasers could potentially attain these tankers for an en-bloc sales price of $291 million, as long as they confirm their unconditional acceptance by June 30, 2015. Other than the sales price, all other material terms and conditions of this potential transaction mirror the terms and conditions on the sale of the four Suezmax tankers, counting a 20% upfront payment to DryShips.
DryShips Inc. provides ocean transportation services for drybulk and petroleum cargoes, and offshore deepwater drilling services. The corporation operates through Drybulk, Tanker, and Drilling segments.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. (ZIOP), and Intrexon Corporation (XON) declared their oncology programs will be strengthened through Intrexon’s new global partnership focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, counting upfront payment, milestones and royalties, equally with ZIOPHARM.
Under the partnership Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its contract with Intrexon, ZIOPHARM will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug (IND) stage, the programs will be transferred to Merck Serono for clinical development and commercialization. ZIOPHARM and Intrexon will also independently conduct research and development on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. ZIOPHARM’s other oncology programs will continue through its Exclusive Channel Partnership(ECC) with Intrexon.
ZIOPHARM Oncology, Inc., a biotechnology corporation, focuses on acquiring, developing, and commercializing cancer therapies. The corporation is employing novel gene expression, and control and cells technologies to deliver cell-based therapies for the treatment of cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
